What Happened?

On May⁢ 10, 2024,⁢ a law ‌firm ⁣representing ⁢healthcare fraud whistleblowers filed ⁢suit against UnitedHealth ​Group, ⁣alleging the company improperly utilized the quantaflo test to increase payments received ‍from the Medicare program. This action followed the⁤ unsealing of federal court documents revealing the Department of Justice’s decision not to ⁢directly pursue a case against UnitedHealth Group. The DOJ‍ did ⁢ reach settlements with other parties involved.

Simultaneously, the DOJ announced a $29.75 million settlement with Semler Scientific, the‍ manufacturer of the QuantaFlo test, resolving fraud claims related to ‍its‍ marketing and billing practices. A separate $7.2⁣ million‍ agreement was reached with CR Bard, the former distributor of QuantaFlo, now owned by Becton, Dickinson and Company (BD) (U.S.Department of Justice,⁢ May 10, 2024).

The QuantaFlo Test and Medicare Billing

QuantaFlo is a non-invasive test​ used to detect peripheral ⁣artery disease (PAD), ‌a condition where narrowed arteries reduce ⁤blood flow to the‌ limbs. Medicare reimburses for PAD testing,but the lawsuit alleges UnitedHealth Group encouraged or facilitated improper billing for the QuantaFlo test,possibly inflating ⁤claims and misusing taxpayer funds.

The DOJ’s settlements with Semler ⁤Scientific and ​CR ‍Bard centered on allegations that the companies misrepresented the capabilities of the QuantaFlo‍ test‌ and encouraged providers ‍to bill Medicare for services that didn’t meet established coverage ⁢requirements. Specifically, the DOJ⁢ alleged Semler Scientific promoted QuantaFlo as a ⁤diagnostic ⁤tool for all stages‍ of PAD, even though Medicare coverage was limited to specific, more severe cases ‍ (U.S. Department​ of ⁤Justice, ⁤May 10, 2024).

Understanding Medicare Coverage for PAD Testing

Medicare ⁣National Coverage Determinations (NCDs) dictate the ​conditions under‌ which PAD testing is covered. Coverage typically requires documented​ symptoms consistent with ‍notable arterial obstruction ‍and is often​ limited to patients being evaluated​ for potential intervention, ⁣such as angioplasty or bypass surgery. ⁣ Billing for QuantaFlo in cases not meeting these criteria could be ‍considered fraudulent.

The DOJ’s Decision ⁣and the whistleblower Lawsuit

The Department of Justice’s decision⁣ not⁢ to intervene directly against UnitedHealth Group is a common occurrence in qui tam cases – lawsuits brought ‍by whistleblowers on ⁢behalf‍ of the government. Under the‌ False Claims Act, whistleblowers can pursue ‍cases independently even if the DOJ declines to join.⁣ The whistleblower retains a portion of any recovered funds if ‍accomplished.

Isaac‌ Bledsoe, acting special agent in charge of the Health and Human Services Department Office of Inspector General, stated, “medical device companies that misrepresent the capabilities of their ⁣products and encourage providers to bill Medicare for‌ services that do not meet coverage requirements drain critical taxpayer-funded ‍resources” ⁢ ​ (U.S. Department of Justice, May 10, 2024). This statement underscores ⁣the government’s focus on preventing⁣ fraud⁣ within the healthcare system.